Oral sulodexide 50 mg/day for 6 months significantly reduced albumin excretion rate to 42.7% of baseline (95% CI, 37.8%-48.2%; p<0.0001) in patients with diabetic nephropathy.
Observational (n=237)
Sí
Does oral sulodexide 50 mg/day reduce albumin excretion rate in diabetic patients with nephropathy?
Low-dose oral sulodexide significantly reduces the albumin excretion rate in patients with diabetic nephropathy over a 6-month period.
valor p: p=<0.0001
Abstract Background: Diabetic nephropathy (DN) is the single greatest cause of end-stage renal disease (ESRD). Without specific interventions, microalbuminuria (incipient nephropathy) gradually progresses to macroalbuminuria (overt nephropathy) within 10-15 years in about 80% of type 1 and 30% of type 2 diabetic patients, and to ESRD within further 20 years in about 75% and 20%, respectively. A primary alteration in DN consists of decreased concentration of glycosaminoglycans (GAGs) in the glomerular extracellular matrix. This evidence has prompted interest in using exogenous GAGs and specifically sulodexide in DN treatment. Patients and methods: In this uncontrolled multicenter study, diabetic patients with albumin excretion rate (AER) ≥30 mg/24 hours were treated with oral sulodexide 50 mg/day for 6 months, while receiving concomitant medication as required. Two hundred thirty-seven patients (54% males and 46% females, mean age 55 years, mean diabetes duration 11 years) were evaluated; 89% had type 2 and 11% type 1 diabetes mellitus, 67% microalbuminuria and 33% macroalbuminuria. Results: AER was significantly and progressively reduced during sulodexide treatment (p0.0001) geometric mean after 3 and 6 months was 63.7% (95% confidence interval 95% CI, 59.3%-68.4%) and 42.7% (95% CI, 37.8%-48.2%) of baseline, respectively. The reduction was similar in type 1 and type 2 diabetes and was slightly greater in macroalbuminuric than in microalbuminuric patients. Blood pressure was slightly lowered, while fasting glucose and glycosylated hemoglobin were moderately reduced. Adverse effects were observed in 5.5% of patients, including gastrointestinal in 3.8%. Conclusions: Sulodexide therapy was shown to reduce AER in patients with DN.
Investigators et al. (Thu,) conducted a observational in Diabetic nephropathy (n=237). oral sulodexide was evaluated on albumin excretion rate (AER) (95% CI 37.8%-48.2%, p=<0.0001). Oral sulodexide 50 mg/day for 6 months significantly reduced albumin excretion rate to 42.7% of baseline (95% CI, 37.8%-48.2%; p<0.0001) in patients with diabetic nephropathy.